Sea Sickness Clinical Trial
Official title:
Video Head Impulse Test and Seasickness Susceptibility
Verified date | December 2022 |
Source | Medical Corps, Israel Defense Force |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This a case control study on seasickness susceptibility. 86 healthy maritime personal were divided to seasickness susceptible and non susceptible groups based on a seasickness questionnaire (Golding) and motion sickness score. All subjects from both groups underwent video head impulse testing (vHIT). VHIT parameters - gain, asymmetry ect were compared between both groups.
Status | Completed |
Enrollment | 86 |
Est. completion date | May 1, 2020 |
Est. primary completion date | May 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - 18-40 healthy military naval subjects - At least six month of active sailing. Exclusion Criteria: - A history of hearing loss - Ear pathology observed at otoscopic examination - A neck injury precluding head movement. - Abnormal otoneurological examination findings - Subject's withdrawal of informed consent. - Failure to complete the video head impulse test. |
Country | Name | City | State |
---|---|---|---|
Israel | Israeli Naval Medical Institute | Haifa |
Lead Sponsor | Collaborator |
---|---|
Medical Corps, Israel Defense Force |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | vHIT gain | measurement of semicircular canal function | Immediate | |
Primary | paired semi-circular canal asymmetry | (|1st canal gain-2nd canal gain|)/(1st canal gain+2nd canal gain) | Immediate | |
Secondary | anterior semicircular canal gain o ipsilateral horizontal canal gain | anterior semicircular canal gain o ipsilateral horizontal canal gain | Immediate |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02911402 -
Motion Sickness on Astrolabe's Vessel
|
||
Recruiting |
NCT05886660 -
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
|
Phase 2 |